Kornimate/medical-research-clean huggingface dataset:
car-t for r/r b-nhl

Conditions: Relapsed Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; CAR - T CD19/CD20/CD22/CD30

Summary: this study is a single arm study to investigate the efficacy and safety of car-t targeted cd19/cd20/cd22/cd30 in relapse and refractory non-hodgkin lymphoma patients. ten patients will recruieted, admitted in hospital for 1 month for the car-t treatment and follow-up for at least 2 years.


Eligibility criteria:
inclusion criteria: * histological detection confirmed cd19/cd20/cd22/cd30 postive non-hodgkin lymphoma * recieved more than 2 lines of chemotherapy * with contraindications of hematopoietic stem cell transplantation or relapse after hematopoietic stem cell transplantation * expected survival more than 3 months * karmofsky performance score ≤ 60, and ecog ≥ 2. * enough organ function: ef≥50%; normal ecg; ccr≥40ml/min; alt and ast ≤ 3 × upper limitation of normal, t-bil ≤ 2.0mg/dl; pt and aptt \ 92% * cbc results: hb ≥ 80g/l, anc \> 1 × 10e9/l, plt ≥ 50 × 10e9/l * results of pregnant test should be negative, and agree to conception control during treatment and 1 year after car-t infusion * with measurable disease * written informed consent could be acquired exclusion criteria: * received immunol suppression treatment or steroids in recent 1 week before recruitment * uncontrolled infection * hiv positive patients * active hbv or hcv infection * women in pregnancy and lactation * refuse to conception control during treatment and 1 year after car-t infusion * uncured malignancies other than non-hodgkin lymphoma * have participated similar trial for treating relapse/refractory non-hodgkin lymphoma * inheritated immune deficiancy * severe heart disease

Keywords: relapse/refractory non-hodgkin lymphoma car - t cd19/cd20/cd22/cd30
coqun study - (coqun): a study to evaluate the effects of coqun in patients affected by open-angle glaucoma

Conditions: Open Angle Glaucoma

Summary: this is a randomized, parallel arm, multicenter, double-blind trial. patients with poag will be randomized 1:1 ratio to receive: * prostaglandin analogue (pga) monotherapy + coqun® (arm a) * prostaglandin analogue (pga) monotherapy + vehicle (arm b)

coqun® 10 ml is a medical device marked by the european community as class iib. this device has a system of dispensation that permits it to be preservative free (osd - ophthalmic squeeze dispenser). investigators and patients will be masked to the study treatment. in order to mask the treatment, identical kit boxes, identical packaging (bottles and labels) will be used for vehicle and active product. the bottles will be dispensed sealed to the patient. one or two drops of the solution (coqun® or vehicle) will be instilled in the conjunctival sac of both eyes, twice daily from 8 to 10 am and from 8 to 10 pm. hypotensive therapy should be administered in the evening one hour after the coqun® or vehicle administration. at baseline, ocular hypotensive treatment, as per inclusion criteria has to be a pga monotherapy. during the follow-up, in case the iop exceeds 28 mmhg, any additional hypotensive therapy will be allowed to obtain iop control. dose modifications/reductions of coqun® /vehicle are not permitted.

Eligibility criteria:
inclusion criteria: 1. patients with diagnosis of poag (monolateral or bilateral) with an iop ranging from 17 to 21 mm hg (at the last performed visit and confirmed at the baseline study visit) on treatment with a topical prostaglandin analogue (pga) monotherapy. 2. vf examination at randomization: vf mean defect (md) at baseline within -4 decibel (db) and -10db and vf pattern standard deviation (psd) within 4 db and 10db (stage 2-3 per the enhanced glaucoma staging system 2 (gss) determined by humphrey field analyzer ii-i, program 30-2 sita standard. 3. in order to determine patient's reliability to perform vf examination: before baseline vf, at least two reliable vf examinations during the last year had to be performed. visual fields are considered reliable if false-positive responses are fewer than 15% and a clear blind spot could be seen in the vf printouts, threshold value \<10 db. 4. age \>40 years 5. provision of informed consent prior to any study specific procedures exclusion criteria: 1. secondary glaucoma (exofoliative glaucoma, pigmentary glaucoma, neovascular glaucoma). 2. abnormalities of the anterior segment of the eye that could affect iop assessment. 3. cornea abnormalities with entities that could affect iop evaluation. 4. other conditions different from glaucoma that could cause vf abnormalities (degenerative myopia, diabetic retinopathy, maculopathy, other optic nerve abnormalities that could mimic glaucoma damage). 5. bcva) \< 0.5 snellen decimal fraction 6. any previous ocular surgery except for uncomplicated cataract extraction and yag laser capsulotomy, laser glaucoma surgeries (argon laser trabeculoplasty and/or selective laser trabeculoplasty). 7. pregnancy or breast-feeding.
eye health in children and adolescents: repeated cross-sectional survey

Conditions: Visual Acuity

Summary: the investigator will take a mixed-methods approach to gather relevant information from both children or adolescents, and their parents on profiles of eye health, as well as routinely available indicators. this includes a series of baselining and follow-up analyses of cohort data collected on epidemiological, clinical, therapeutic, and service aspects of eye health and individual-level outcomes

the investigator will take a mixed-methods approach to gather relevant information from both children or adolescents, and their parents on profiles of eye health, as well as routinely available indicators. this includes a series of baselining and follow-up analyses of cohort data collected on epidemiological, clinical, therapeutic, and service aspects of eye health (e.g., social environment, preventive behaviours, risk factors, knowledge and attitudes, health and social care, etc.) and individual-level outcomes (e.g., clinical parameters and symptoms, biomarkers, self-reported measures, risk profiles, etc.).

Eligibility criteria:
inclusion: * subjects with valid information on eye health-related profiles * completion of eye health examination delivered by trained ophthalmic professionals exclusion: * inability to give informed consent * unable to retrieve individual records on eye health examination
computerised intervention/treatment for adolescent depression and low mood:

Conditions: Depression

Summary: this study forms the second phase of previous work to examine the effectiveness of computerised cognitive behaviour therapy (ccbt) to treat adolescents with low mood/depression. depression affects around 2% of adolescents. antidepressants are not recommended for this age range as a first line treatment because of concerns about their usefulness and side effects. government guidelines have supported using cognitive behaviour therapy (cbt), which is effective and one of the main treatments recommended for depression. it has been suggested that computerised versions of cbt (ccbt) may be effective for treating depression in young people who may prefer this to seeing a therapist face-to-face, but little research exists to date to support this. this study examines the feasibility of running a large scale randomised controlled trial (rct) to compare a promising ccbt program (stressbusters) with self-help websites for adolescents with low mood and depression (lmd). eligible and consenting participants will complete several questionnaires to assess their mood before being randomly assigned to either ccbt (stressbusters) or equivalent access to selected websites providing self help for lmd. participants will complete further mood questionnaires 4 and 12 months after treatment completion/withdrawal. we have already recruited 97 individuals to this trial but aim to recruit a further 48 participants to collect further information. we are also keen to find out whether sending participants text messages before sessions and around follow up periods will increase attendance/completion. therefore all trial participants will receive text messages from the research team during their participation.


Eligibility criteria:
inclusion criteria: * 12 to 18 years * low mood/depression * co-morbid physical illness or co-morbid non-psychotic functional disorders, such as anxiety exclusion criteria: * suicidality * postnatally depressed * suffering psychotic symptoms

Keywords: computerised cognitive behaviour therapy adolescents depression low mood
the effects of sphenopalatine ganglion acupuncture in patients with seasonal allergic rhinitis

Conditions: Patients

Summary: sphenopalatine ganglion (spg)-acupuncture has been shown to exhibit distinct effects in treatment of nasal inflammatory disease. investigators aimed to assess the effects of spg acupuncture in patients with seasonal allergic rhinitis. the randomized, double-blind, controlled clinical trial enrolled participants with seasonal allergic rhinitis. participants will be randomly assigned to either active spg-acupuncture group or sham-acupuncture group. all participants will be provided four times of acupuncture in 4 weeks, and then follow-up of 4 week. primary trial outcomes are change in symptoms and change in need for medication. the primary outcomes will be measured in baseline, week1, week2, week3, week4, week 6 and week 8. secondary outcomes include the changes in nasal patency (nasal airway resistance and nasal cavity volume), exhaled nasal nitric oxide.the investigators also evaluate change in neuropeptides (substance p, vasoactive intestinal peptide,neuropeptide y) and inflammatory cytokines (interleukin(il)-4, il-5, il-8, il-17a, il-22, il-25, interferon-γ, tumor necrosis factor-α, transforming growth factor(tgf)-β1, tgf-β2, tgf-β3,chemokine, eotaxin) in nasal secretions as secondary outcomes. the secondary outcomes will be measured in baseline, week1, week4 and week 8.


Eligibility criteria:
inclusion criteria: * patients with a history of at least 2 years of seasonal allergic rhinitis * no smoking * without history of nasal polyps, nasal septum deviation and history of nose surgery) or lung disease (asthma, chronic obstructive pulmonary disease and fibrosis) * free of upper and lower respiratory tract infections for at least 4 weeks before beginning the study. exclusion criteria: * had received acupuncture within the last four weeks before the study * history of diabetes mellitus, autonomic neuropathy, coronary heart disease or hypertension.

Keywords: acupuncture sphenopalatine ganglion allergic rhinitis randomized trial
prolonged protection from bone disease in multiple myeloma

Conditions: Multiple Myeloma

Summary: main hypothesis: patients who continue zoledronic acid after year 2 have longer time until progression in bone disease compared to patients who stop treatment after two years? secondary hypothesis: serum will bone markers increase prior to progression in bone disease in the individual patient? secondary hypothesis: low-dose ct will detect more cases of osteolytic bone disease in multiple myeloma compared to conventional radiography

newly diagnosed myeloma patients will be followed for 4 years. the first two years they will be treated with zoledronic acid monthly. at year 2 they will be randomized to a continue treatment for 2 more years or b stop treatment. the primary outcome of the study will be time to progressive bone disease from year 2 and onward. serum bone markers will be measured throughout the study. in patients who experience progressive bone disease, development of bone markers prior to the radiological progression will be investigated to see the if it could have been predicted with the use of serum markers during the four year period patients will have low-dose ct superior and conventional radiography made at predefined time points. the secondary outcome of the study is to compare the sensitivity of the two modalities

Eligibility criteria:
inclusion criteria: * symptomatic multiple myeloma regardless of bone disease status * signed informed consent * age ≥ 18 years * remaining life expectancy ≥ 2 years * any concurrently anti-myeloma treatment are allowed exclusion criteria: * previous treatment with bisphosphonate within the last 6 months * severely reduced renal function (creatinine clearance \<30 ml/min despite fluid replacement) * known concurrent malignancy, excluding skin cancer * known hypersensitivity to zoledronic acid * pregnant or lactating women * women of childbearing potential or men engaging in sexual activity with a woman of childbearing potential who refuse to use contraception

Keywords: osteolysis zoledronic acid osteonecrosis bone markers low-dose ct
the plan and stand study: reducing sitting time in breast cancer survivors

Conditions: Breast Neoplasms

Summary: excessive sitting time (sedentary time) has been associated with risk of insulin resistance and other factors which may be relevant to breast cancer prognosis. this 8-week study tests different strategies for helping breast cancer survivors to modify their levels of sitting time. participants will be assigned with equal likelihood to one of three groups (1) overall reduction in sitting time, (2) interruption of sitting time with standing breaks, and (3) usual care.


Eligibility criteria:
inclusion criteria: 1. diagnosed with stage 0-iii breast cancer. bilateral or multiple primary breast cancers are permitted. 2. completed primary treatment defined as definitive surgery, (neo)adjuvant chemotherapy and/or (neo)adjuvant radiation. participants still receiving adjuvant endocrine or her2 targeted therapies are eligible. 3. report sitting for ≥8 accumulated waking hours on a typical day, 4. willing and able to attend 3 study visits at the uw, 5. willing to attempt reduction of sitting time, 6. use the internet on a regular basis, 7. willing and able to complete study requirements, and 8. currently considered postmenopausal (no menstrual periods in past 12 months), even if pre-menopausal at diagnosis. exclusion criteria: 1. evidence of recurrence or metastatic disease, 2. unable to move from sitting to standing without difficulty and to walk 1 block.
follow-up of cell changes in the cervix

Conditions: Cancer of Cervix

Summary: the purpose of the study is to follow up on cell changes detected in the cervical cancer screening program, to investigate whether they are handled with adequate quality.

the aim of the study is to clarify whether follow-up of cell changes is carried out with sufficiently good quality. it is nationally recommended to perform an hpv test on mild cell changes and only refer to clinical follow-up if you are hpv positive. descriptive statistics on hpv-testing and follow-up of quality are not available today. if hpv testing has not already been performed, archived samples with glandular cell changes will be hpv-analyzed in cobas 4800 hpv-polymerase chain reaction (pcr), which shows data on the presence of hpv and luminex-pcr, which shows which hpv types the samples have. women with low-grade squamous cell changes (ascus and cin1) with simultaneous hpv analysis will be followed up with data from the swedish national cervical screening registry (nkcx) from the last ten years. a register linkage with data from nkcx and the national cancer registry at the national board of health and welfare will be carried out to determine which women have developed gynecological cancer, cervical cancer and/or pre-cancer (cancer in situ). a follow-up review of reported original cytological (cell samples) and histological (tissue samples) diagnoses will be performed by cytodiagnostics and cytopathologists, to verify the correct diagnosis. statistics on collection of non-organized cell samples after a partial negative sample where follow-up is not recommended are produced in aggregated form in the form of an extract from nkcx

Eligibility criteria:
inclusion criteria: * women with an agc diagnosis between february 17, 2014 and december 31, 2018 * 23-80 years old * resident of the stockholm-gotland region of sweden exclusion criteria: -
evaluation the possible influence of transcatheter arterial chemoembolization on hepatitis b viral replication

Conditions: Hepatocellular Carcinoma; Hepatitis B Virus

Summary: transcatheter arterial chemoembolization (tace) is the traditional method for the palliative management of patients with hepatocellular carcinoma (hcc). few previous studies had demonstrated that the serum level of anticancer drug from patients treated by tace was similar to those treated by systemic chemotherapy. since systemic chemotherapy may have the possibility to influence patient's general defense ability, hepatitis b virus may reactivate after chemotherapy.this study is to investigate the possibility of tace in the reactivation of hepatitis b virus.

hepatocellular carcinoma (hcc) is the most common malignant tumor of the liver. chronic hepatitis b infection is the common etiology for the development of hcc. transcatheter arterial chemoembolization (tace) is the traditional method for the palliative management of patients with hcc. few previous studies had demonstrated that the serum level of anticancer drug from patients treated by tace was similar to those treated by systemic chemotherapy. since systemic chemotherapy may have the possibility to influence patient's general defense ability, hepatitis b virus may reactivate after chemotherapy. there is no study to investigate the possibility of tace in the reactivation of hepatitis b virus. this project will collect 20 patients with hcc caused by hepatitis b who are planned to be treated by tace. quantitative determination of viral load in blood will be performed before tace, the first and the third month after tace to investigate the influence of tace on hepatitis b virus replication. this study will not influence the doctor's decision in the management of hcc and the procedure of tace. the serum used for hbv dna examination is concomitantly obtained during regular blood sampling for tace preparation and follow-up of patient. the amount of blood needed for each time hbv dna examination is less than 10 ml.

Eligibility criteria:
inclusion criteria: * patients with hepatocellular carcinoma caused by hepatitis b virus without antiviral drug treatment and patients will be treated by transcatheter arterial chemoembolization exclusion criteria: * patients already received antiviral drug management

Keywords: hepatocellular carcinoma hepatitis b virus transcatheter arterial chemoembolization
technology intervention for diabetes engagement & self-care (tides)

Conditions: Diabetes Mellitus Type 2

Summary: the purpose of this 3 site, 24-week, comparative effectiveness randomized clinical trial in primary care is to compare usual care to an online, multi-media, digital intervention for persons with type 2 diabetes to improve engagement, knowledge, and self-care.

objective: technology shows promise to enhance standard care of diabetes with cost-effective, online lifestyle interventions. compared to primary care (pc) diabetes system of care (control), the investigators hypothesized technology intervention for diabetes engagement \& self-care (tides) would significantly improve diabetes knowledge and self-care. methods: following institutional review board (irb) approval, physician letters were sent to patients with type 2 diabetes, age \>18 years with hga1c \>8% identified via electronic health record (ehr) of an integrated us health system to invite participation in a 3-site, 24-week diabetes study. of the 270 with \>1 week email/web use invited to the shared medical visit (smv) orientation, 166 subjects provided written informed consent. diabetes knowledge and self-care assessments, vital signs, hga1c, fasting glucose and lipids were collected at baseline, 3 and 6 months. following randomization to tides (n=117) or usual care (n=49), tides group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slide shows, food solutions, expert questions and answers,and quizzes.

Eligibility criteria:
inclusion criteria: * diabetes mellitus type 2 * geisinger primary care provider * access to a computer exclusion criteria: * severe medical problems that limits travel to primary care * diabetes type 1 * cognitive impairment * taking anti-psychotic meds

Keywords: diabetes internet education diabetes education diabetes self-care diabetes self-management diabetes behavior intervention
early hydration in acute myocardial infarction

Conditions: Contrast Induced Acute Kidney Injury

Summary: the purpose of this study is to determine whether hydration with sodium bicarbonate is more effective than hydration with sodium chloride to prevent contrast nephropathy in patients undergoing primary coronary intervention for acute st elevation myocardial infarction.


Eligibility criteria:
inclusion criteria: * consecutive patients with ami candidates for primary pci presenting within 12 h of symptom onset with st-segment elevation of more 1 mm in at least two contiguous leads of electrocardiogram. exclusion criteria: * contrast medium administration within the 10 days * end-stage renal failure requiring dialysis * refusal to give informed consent

Keywords: contrast-induced nephropathy contrast media angiography coronary percutaneous intervention
endosponge vacuum therapy (e-vac) registry of intestinal anastomotic leaks and perforations

Conditions: Intestinal Anastomotic Leak; Intestinal Perforations

Summary: the purpose of this registry is to collect data on the clinical use of endoluminal vacuum (e-vac) therapy to treat both upper and lower intestinal leaks and perforations.


Eligibility criteria:
inclusion criteria: * all patients undergoing e-vac therapy * age \> 17 years exclusion criteria: * 17 years of age or younger * undergone an e-vac placement \> 14 days before consenting
intra-articular glucocorticoid treatment of the elbow

Conditions: Rheumatoid Arthritis

Summary: background: intra-articular glucocorticoid injections are frequently used to relieve symptoms of arthritis. postinjection rest has been shown to improve the outcome of knee joint injections, but not for wrist injections. consequently, different joints respond differently on postinjection regimens. objectives: to investigate whether better treatment results might be achieved of post-injection rest following intra-articular glucocorticoid treatment for elbow synovitis. methods: 90 patients with rheumatoid arthritis (ra) and elbow synovitis were treated with 20 mg intra-articular triamcinolone hexacetonide and randomised to either a 48 hour immobilisation in a triangular sling (n=46) or normal activity without restrictions (n=44). primary endpoint was relapse of synovitis. in addition, pain, function according to a self assessment questionnaire (pree) and range of movement were followed for six months.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis, and * clinical signs of elbow synovitis exclusion criteria: * patients in function class 4 according to steinbrocker as well as patients with oral glucocorticoid treatment corresponding to more than 7.5 mg prednisolone or intra-articular treatment in the joint the past three months

Keywords: rheumatoid arthritis treatment
treatment for patients with gynecological malignancies who suffer from anemia due to chemotherapy

Conditions: Gynecological Malignancies; Genital Neoplasms, Female; Anemia

Summary: the purpose of this study is to validate a patient satisfaction questionnaire for anemia treatment (psq-at) in gynecological cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rhuepo) for anemia due to chemotherapy.


Eligibility criteria:
inclusion criteria: - subjects receiving multi-cycle chemotherapy for gynecological cancer - anemia due to chemotherapy (hgb less than or equal to 11.0 g/dl) - expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment - karnofsky performance scale (kps) greater than or equal to 50% - adequate renal function - adequate liver function exclusion criteria: - iron deficiency - known positive test for human immunodeficiency virus (hiv) infection

Keywords: uterine cancer ovarian cancer darbepoetin alfa amgen gynecological malignancies